Citations

Clear

2 citation(s) found for "Smith, Victoria".

Matrix metalloproteinase-9 deficiency confers resilience in fibrodysplasia ossificans progressiva in a man and mice
Lounev, Vitali, Groppe, Jay C. , Brewer, Niambi , Wentworth, Kelly L. , Smith, Victoria , Xu, Meiqi , Schomburg, Lutz , Bhargava, Pankaj , Mukaddam, Mona Al , Shore, Eileen M. , Pignolo, Robert J. , Hsiao, Edward C. , Kaplan, Frederick S.

Mayo Clinic

Journal of Bone and Mineral Research | February 17, 2024 | Volume: 39 | Issue: 4 | Pages: 382-398

10.1093/jbmr/zjae029 | PMID 38477818 Get It

Abstract Single case studies of extraordinary disease resilience may provide therapeutic insight into conditions for which no definitive treatments exist. An otherwise healthy 35-year-old man (patient-R) with the canonical pathogenic ACVR1R206H variant and the classic congenital great toe malformation of fibrodysplasia ossificans progressiva (FOP) had extreme paucity of post-natal heterotopic ossification (HO) and nearly normal mobility. We hypothesized that patient-R lacked a sufficient post-natal inflammatory trigger for HO. A plasma biomarker survey revealed a reduction in total matrix metalloproteinase-9 (MMP-9) compared to healthy controls and individuals with quiescent FOP. Whole exome sequencing identified compound heterozygous variants in MMP-9 (c.59C > T, p.A20V and c.493G > A, p.D165N). Structural analysis of the D165N variant predicted both decreased MMP-9 secretion and activity that were confirmed by enzyme-linked immunosorbent assay and gelatin zymography. Further, human proinflammatory M1-like macrophages expressing either MMP-9 variant produced significantly less Activin A, an obligate ligand for HO in FOP, compared to wildtype controls. Importantly, MMP-9 inhibition by genetic, biologic, or pharmacologic means in multiple FOP mouse models abrogated trauma-induced HO, sequestered Activin A in the extracellular matrix (ECM), and induced regeneration of injured skeletal muscle. Our data suggest that MMP-9 is a druggable node linking inflammation to HO, orchestrates an existential role in the pathogenesis of FOP, and illustrates that a single patient’s clinical phenotype can reveal critical molecular mechanisms of disease that unveil novel treatment strategies.
When all seems lost: management of refractory constipation—Surgery, rectal irrigation, percutaneous endoscopic colostomy, and more
Wilkinson‐Smith, Victoria , Bharucha, Adil E. , Emmanuel, Anton , Knowles, Charles H. , Yiannakou, Y., Corsetti, Maura , Wilkinson-Smith, V , Bharucha, A E , Corsetti, M , Yiannakou, Y.

Mayo Clinic

Neurogastroenterology & Motility | April 27, 2018 | Volume: 30 | Issue: 5 | Pages: No page available

10.1111/nmo.13352 | PMID 29700961 Get It

AbstractWhile the pharmacological armamentarium for chronic constipation has expanded over the past few years, a substantial proportion of constipated patients do not respond to these medications. This review summarizes the pharmacological and behavioral options for managing constipation and details the management of refractory constipation. Refractory constipation is defined as an inadequate improvement in constipation symptoms evaluated with an objective scale despite adequate therapy (ie, pharmacological and/or behavioral) that is based on the underlying pathophysiology of constipation. Minimally invasive (ie, rectal irrigation and percutaneous endoscopic colostomy) and surgical therapies are used to manage refractory constipation. This review appraises these options, and in particular, percutaneous endoscopic colostomy, which as detailed by an article in this issue, is a less invasive option for managing refractory constipation than surgery. While these options benefit some patients, the evidence of the risk: benefit profile for these therapies is limited.